| Objective: Study governor meridian moxibustion therapy for pulmonary allergic rhinitis the clinical efficacy of spleen-deficiency type,observe the governor meridian moxibustion therapy in patients with pulmonary spleen-deficiency type allergic rhinitis the clinical symptoms,signs and the visual simulation of the rating scale(VAS)symptoms integral to improve the situation,to patients before and after treatment in nasal secretions eosinophils(EOS)count,the influence of the number of valid within half a year after treatment of allergic rhinitis recurrence rate and recurrent symptoms for the first time a severity compared before treatment,verify its efficacy and safety of the clinical treatment,governor meridian moxibustion therapy in the treatment of this disease and preliminarily verifier mechanism,provides a scientific theory for clinical application and popularization.Method: Collected in June 2015 to October 2016 in the second clinical medical college of henan university of TCM(Chinese medicine hospital in henan province)the otolaryngology clinic patients willing to join in this topic research,and included in the standard of 80 cases of lung deficiency in patients with allergic rhinitis,temper and ra-ndomly divided into control group and treatment group(40 cases each.The control g-roup given furoic acid mo betamethasone nasal spray nasal nasonex,oral and left cetirizine hydrochloride dispersible tablet,four weeks for a period of treatment;Treatment group was treated in the control group,on the basis of joint governor meridian mox-ibustion therapy,1 times a week,four times,four weeksfor a period of treatment.Were observed 1 course of treatment.Before the treatment after(30 days)in patients with symptoms,signs,VAS quantitative table symptom scores,nasal secretions eosinophil count,and treatment of patients with a valid half a year first relapse or recurrence of symptoms was severity is checked with the records,after the observation on the clinical observation indexes data processing and statistical analysis.Results: 1,the total effective rate comparison: treatment group total effective rate was97.22%,control group total effective rate was 80.56%.The two groups after treatment on the total effective rate statistical differences(P < 0.05).2,signs and symptoms curative effect comparison: comparison group,two groups of symptoms(stuffy nose,nasal itching,sneezing,qing stuff),quantitative signs integral statistical differences compared before and after the treatment(P < 0.05);Comparison between groups,two groups of patients' symptoms and signs before quantitative integral treatment was no significant difference(P > 0.05),after treatment in the presence of statistical significance(P < 0.05).3,visual simulation of quantitative table score(VAS)comparison:comparison group,control group in a stuffy nose,nasal itching,sneezing,qing stuff,smell drops,itchy,watery eyes,pharyngeal itching,symptoms such as cough,before and after treatment comparison there is statistical significance(P > 0.05),in the whole body symptoms such as chills,fatigue,no statistical significance before and after treatment(P < 0.05),the treatment group of VAS each symptom score before and after treatment were statistically significant(P > 0.05);Group comparison: two groups before treatment VAS were no statistical significance of each symptom integral comparison,after treatment,two groups of patients with improved AR cure itchy,watery eyes,pharyngeal itching,coughing etc.There is no statistical difference of adjoint symptoms(P > 0.05),and in improving the stuffy nose,nasal itching,sneezing,qing stuff,hyposmia,chills,loose stools,with statistical differences.4,nasal secretions in the EOS counts: group comparison: two groups before and after treatment are statistically significant(P < 0.05),;Group comparison: between two groups before treatment in nasal secretions EOS count there is no statistical significance(P > 0.05),after treatment,two groups have statistical difference(P < 0.05).5,Cure patients with effective after half year relapse rate comparison: the control group recurrence rate was75.86%,the treatment group recurrence rate was 34.29%.The two groups have statistical significance(P < 0.05);For the first time the severity of the symptoms of recurrence compared with before treatment,two groups have statistical significance(P< 0.05).6,safety comparison: two groups before and after the treatment of the patient's vital signs(temperature,respiration,pulse and blood pressure)and the blood and urine routine examination,no adverse changes associated with drug treatment,no serious adverse events occurred during the observation.Conclusion: 1,governor meridian moxibustion can significantly reduce the main symptoms and signs of allergic rhinitis,decreased to improve the sense of smell,chills,loose stools with symptoms,such as clinical curative effect is distinct,worthyof promotion;2,governor meridian moxibustion can significantly reduce the EOS count in the patients with allergic rhinitis nasal secretions;3,governor meridian moxibustion can reduce the recurrence of allergic rhinitis,reduce the recurrence of symptoms;4,governor meridian moxibustion the small probability of occurrence of adverse events in this study,and minor symptoms,did not affect patient's life,therefore,this therapy is safe and effective,reliable and found no significant side effects,worthy of promotion. |
PDF Full Text Request